[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-biomarkers-and-clinical-trials":3},{"id":4,"title":5,"author":6,"body":7,"category":268,"description":269,"extension":270,"featured":271,"image":272,"meta":273,"navigation":274,"path":275,"publishedAt":276,"readingTime":277,"seo":278,"status":279,"stem":280,"__hash__":281},"blog\u002Fblog\u002Fbiomarkers-and-clinical-trials.md","Biomarkers and clinical trials: how your tumor's profile can open doors","Nilu Kundagrami",{"type":8,"value":9,"toc":257},"minimark",[10,23,26,31,34,41,45,48,56,59,157,160,164,167,170,174,181,201,214,218,221,247,251],[11,12,13,14,18,19,22],"p",{},"A generation ago, a cancer was mostly described by where it started and how far it had spread — \"stage III breast cancer,\" \"metastatic lung cancer.\" That's still important. But increasingly, the question that decides your treatment options isn't just ",[15,16,17],"em",{},"where"," the cancer is. It's ",[15,20,21],{},"what's driving it"," at the molecular level. That's what a biomarker tells you, and it's quietly become one of the most important things to know when you're looking for a clinical trial.",[11,24,25],{},"If you've been handed a pathology report full of acronyms — EGFR, HER2, ALK, BRAF, PD-L1, KRAS, MSI — this post is for you. Understanding what those markers mean can be the difference between scrolling past a trial and realizing it was designed for exactly your situation.",[27,28,30],"h2",{"id":29},"what-a-biomarker-actually-is","What a biomarker actually is",[11,32,33],{},"A biomarker is a measurable characteristic of your disease — often a specific gene mutation, a protein the tumor overexpresses, or a molecular feature of how the cancer behaves. Doctors find them through tests on your tumor tissue or blood: genomic sequencing, immunohistochemistry, and similar lab work.",[11,35,36,37,40],{},"Think of a biomarker as a detail about the ",[15,38,39],{},"mechanism"," of your disease rather than its location. Two people with what looks like \"the same\" lung cancer can have completely different molecular drivers — one an EGFR mutation, another an ALK rearrangement — and as a result, completely different treatment options and trials open to them.",[27,42,44],{"id":43},"why-biomarkers-increasingly-decide-eligibility","Why biomarkers increasingly decide eligibility",[11,46,47],{},"Modern trials, especially in oncology, are often built around a specific biomarker. A trial might be testing a drug that targets the EGFR mutation, or one that works only when a tumor is PD-L1 high. If the trial is designed for that marker, then having it (or not) can be the single criterion that gets you in or keeps you out.",[11,49,50,51,55],{},"This is the rise of ",[52,53,54],"strong",{},"precision medicine",": matching treatments to the molecular profile of a disease rather than treating everyone with the same diagnosis identically. It's why a biomarker can matter more than your stage when it comes to trial eligibility. It's also why two patients with the same cancer, sitting in the same waiting room, can qualify for entirely different studies.",[11,57,58],{},"Here are a few markers you'll commonly see, purely as examples of the landscape:",[60,61,62,84,98,112,144],"ul",{},[63,64,65,78,79,83],"li",{},[52,66,67,68,73,74],{},"EGFR, ",[69,70,72],"a",{"href":71},"\u002Fbiomarkers\u002Falk-gene","ALK",", ROS1, ",[69,75,77],{"href":76},"\u002Fbiomarkers\u002Fgtpase-kras","KRAS"," — mutations and rearrangements that frequently guide ",[69,80,82],{"href":81},"\u002Fconditions\u002Flung-non-small-cell-carcinoma","lung cancer"," treatment and trials.",[63,85,86,92,93,97],{},[52,87,88],{},[69,89,91],{"href":90},"\u002Fbiomarkers\u002Ferbb2-gene","HER2"," — a protein that, when overexpressed, opens a whole class of targeted therapies and trials, classically in ",[69,94,96],{"href":95},"\u002Fconditions\u002Fbreast-carcinoma","breast cancer"," but increasingly beyond it.",[63,99,100,106,107,111],{},[52,101,102],{},[69,103,105],{"href":104},"\u002Fbiomarkers\u002Fbraf-gene","BRAF"," (often the V600E variant) — central to many ",[69,108,110],{"href":109},"\u002Fconditions\u002Fmelanoma","melanoma"," trials and relevant in other cancers.",[63,113,114,125,126,129,130,129,134,138,139,143],{},[52,115,116,120,121],{},[69,117,119],{"href":118},"\u002Fbiomarkers\u002Fbrca1-gene","BRCA1","\u002F",[69,122,124],{"href":123},"\u002Fbiomarkers\u002Fbrca2-gene","BRCA2"," — mutations that affect options in ",[69,127,128],{"href":95},"breast",", ",[69,131,133],{"href":132},"\u002Fconditions\u002Fmalignant-ovarian-neoplasm","ovarian",[69,135,137],{"href":136},"\u002Fconditions\u002Fprostate-carcinoma","prostate",", and ",[69,140,142],{"href":141},"\u002Fconditions\u002Fpancreatic-carcinoma","pancreatic"," cancers.",[63,145,146,152,153,156],{},[52,147,148],{},[69,149,151],{"href":150},"\u002Fbiomarkers\u002Fprogrammed-cell-death-1-ligand-1","PD-L1 status"," and ",[52,154,155],{},"MSI-high \u002F mismatch-repair status"," — markers that help predict who may benefit from immunotherapy.",[11,158,159],{},"You don't need to memorize these. The point is simpler: your specific markers are keys, and different keys open different doors.",[27,161,163],{"id":162},"how-to-find-out-your-biomarkers","How to find out your biomarkers",[11,165,166],{},"If you don't already know your molecular profile, ask your oncologist whether biomarker or genomic testing has been done, and if not, whether it's appropriate for your situation. Many patients have had testing without fully registering the results, so it's worth requesting a copy of your pathology and any genomic reports. You have a legal right to these records.",[11,168,169],{},"Bring the actual report when you search for trials. \"I have lung cancer\" narrows things a little; \"I have EGFR-mutated non-small cell lung cancer\" narrows things enormously — and in the right direction.",[27,171,173],{"id":172},"using-your-profile-to-find-trials","Using your profile to find trials",[11,175,176,177,180],{},"Once you know your markers, you can search ",[15,178,179],{},"with"," them instead of around them. This is where a biomarker turns from a line on a report into a practical tool.",[11,182,183,184,188,189,193,194,152,197,200],{},"On Trialytics, you can ",[69,185,187],{"href":186},"\u002Fbiomarkers","browse recruiting trials by biomarker"," — pick your marker and see the trials built around it. You can also ",[69,190,192],{"href":191},"\u002Fconditions","browse by condition"," and then narrow to the trials that require your specific mutation, which is often how the highest-intent matches surface: the intersection of ",[15,195,196],{},"your diagnosis",[15,198,199],{},"your molecular profile",".",[11,202,203,204,208,209,213],{},"And because eligibility criteria are written in dense medical shorthand, you don't have to interpret them alone. You can ",[69,205,207],{"href":206},"\u002Fsearch","check how your profile lines up against a trial's criteria"," — biomarkers included — in plain language, so you can tell quickly whether a targeted trial is actually open to you. If you've been filtered out of trials before and weren't sure why, our guide to ",[69,210,212],{"href":211},"\u002Fblog\u002Fclinical-trial-eligibility","clinical trial eligibility"," is a good companion to this one.",[27,215,217],{"id":216},"a-few-honest-caveats","A few honest caveats",[11,219,220],{},"Biomarkers are powerful, but they're not magic, and it's worth keeping perspective:",[60,222,223,229,235,241],{},[63,224,225,228],{},[52,226,227],{},"Not every disease is biomarker-driven."," Precision medicine has advanced fastest in oncology; in other conditions, biomarkers may play a smaller role in trial matching.",[63,230,231,234],{},[52,232,233],{},"Markers can change over time."," A cancer can evolve, and a biomarker present at diagnosis may differ after treatment. Re-testing is sometimes warranted — ask your team.",[63,236,237,240],{},[52,238,239],{},"Testing has limits."," Different tests look for different things, and no single panel catches everything. What was tested matters as much as what was found.",[63,242,243,246],{},[52,244,245],{},"A marker is an input, not a verdict."," Qualifying for a trial on paper is the beginning of a conversation with the study team and your doctor, not the end.",[27,248,250],{"id":249},"the-bottom-line","The bottom line",[11,252,253,254,200],{},"Your tumor's molecular profile is one of the most useful things you can bring to a trial search. It can transform an overwhelming list of thousands of studies into a short list built for your specific biology. So get your reports, learn your markers, and search with them in hand. The trials designed for people like you are far easier to find when you know exactly what makes your situation ",[15,255,256],{},"you",{"title":258,"searchDepth":259,"depth":259,"links":260},"",3,[261,263,264,265,266,267],{"id":29,"depth":262,"text":30},2,{"id":43,"depth":262,"text":44},{"id":162,"depth":262,"text":163},{"id":172,"depth":262,"text":173},{"id":216,"depth":262,"text":217},{"id":249,"depth":262,"text":250},"research","What biomarkers are, why they increasingly decide which trials you qualify for, and how to use your molecular profile — EGFR, HER2, BRAF, PD-L1 and more — to find trials built for you.","md",false,"\u002Fimages\u002Fog\u002Fblog\u002Fbiomarkers-and-clinical-trials.png",{},true,"\u002Fblog\u002Fbiomarkers-and-clinical-trials","2026-06-18","9",{"title":5,"description":269},"published","blog\u002Fbiomarkers-and-clinical-trials","OPvAIW1ZvchY3TkGyVNHYJBp6bWnFwirYGM-ylGGeco"]